We studied the effects of interleukin-4 (IL-4) and IL-6 on the growth of leukemic blasts from 40 patients with acute myelogenous leukemia (AML). Patients were selected on the basis of negativity for a series of B-cell antigens including CDlO and CD19. Twenty-one cases were CD34-positive (CD34') ( > 15% of blasts) and the remaining 19 were CD34negative (CD34-) (<3% of blasts). IL-4 alone (100 U/mL) could stimulate either DNA synthesis (with > 2.0 stimulation index) or leukemic blast colony formation in 24 of 40 AML patients. In the presence of other growth factors, IL-4 showed divergent effects on IL-3-, granulocyte-macrophage colonystimulating factor-, granulocyte colony-stimulating factor-, or erythropoietin-dependent colony formation. These effects of IL-4 were observed in both CD34' and CD34-AML cases. IL-6 (I00 U/mL) alone could not stimulate DNA synthesis and blast colony formation except for one CD34' case. On the CUTE MYELOGENOUS leukemia (AML) cells are
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We studied the effects of interleukin-4 (IL-4) and IL-6 on the growth of leukemic blasts from 40 patients with acute myelogenous leukemia (AML). Patients were selected on the basis of negativity for a series of B-cell antigens including CDlO and CD19. Twenty-one cases were CD34-positive (CD34') ( > 15% of blasts) and the remaining 19 were CD34negative (CD34-) (<3% of blasts). IL-4 alone (100 U/mL) could stimulate either DNA synthesis (with > 2.0 stimulation index) or leukemic blast colony formation in 24 of 40 AML patients. In the presence of other growth factors, IL-4 showed divergent effects on IL-3-, granulocyte-macrophage colonystimulating factor-, granulocyte colony-stimulating factor-, or erythropoietin-dependent colony formation. These effects of IL-4 were observed in both CD34' and CD34-AML cases. IL-6 (I00 U/mL) alone could not stimulate DNA synthesis and blast colony formation except for one CD34' case. On the CUTE MYELOGENOUS leukemia (AML) cells are A able to proliferate and form blast colonies in vitro in the presence of various growth factors, including granulocyte-macrophage colony-stimulating factor (GM-CSF),',' granulocyte CSF (G-CSF),'s3 or interleukin-3 (IL-3),4,5 although their response patterns were heterogenous among the patients. The heterogeneity of proliferative capacity of AML cells in response to these hematopoietic growth factors is partly due to the "maturation arrest" of leukemic progenitors at various stages of hematopoietic differentiation. A differentiation antigen of CD34 (MY10, HPCA-l), is a stage-specific rather than a lineage-specific antigen preferentially expressed on normal human progenitor cell^.^^' Recent reports have indicated that in a considerable proportion of AML cases, leukemic blasts expressed a CD34 surface According to the concept of "maturation arrest" in acute leukemia, it is conceivable that the CD34 positivity represents "immature" biologic characteristics of leukemic blasts; a high frequency of CD34 expression may reflect the acute leukemia involving transformation of a primitive stem cell that undergoes limited differentiation. In addition, CD34-positive (CD34') AML was demonstrated to show distinct clinicopathologic features, including poor prognosis associated with a low rate of complete remissiong31o and a relatively high frequency of chromosomal abnormalities involving chromosome 5 or 7,9,'0 which are often identified in patients with myelodysplastic syndromes. These clinicopathologic features suggest that the CD34 expression in AML represents some distinct biologic characteristics, such as involvement of very early stem cells, rather than the abberant expression of the CD34 gene associated with leukemic transformation. However, little has been known concerning the correlation between the CD34 positivity of AML blasts and their responses to various growth factors.
IL-4 was initially described as a costimulator of DNA synthesis for B cells stimulated with anti-IgM antibodies." However, recent studies have demonstrated that IL-4 exerts significant effects on the early stage of hematopoie-other hand, IL-6 showed synergistic effects on IL-3-and IL-edependent blast colony formation in 10 of 12 and 7 of 9 CD34+ AML cases, respectively. Among CD34-AML cases, such synergism was seen only in 1 of 12 cases for IL-3dependent colony formation and in 3 of 7 cases for IL-4dependent colony formation. The divergent effect of IL-4 and the synergistic effect of IL-6 were also observed in purified CD34+ leukemic blast populations, indicating that these phenomena are not mediated by accessory cells. The present study suggests that IL-4, alone or in combination with other growth factors, has divergent effects on the growth of AML progenitors irrespective of the CD34 expression, and that IL-6 acts synergistically with IL-3 or IL-4 on the growth of leukemic progenitors preferentially in CD34' AML. 0 1991 b y The American Society of Hematology. sis; murine IL-4 acts directly on murine marrow cells to form multilineage (CFU-GEMM) colonies" and supports the growth of burst-forming unit-erythroid (BFW-E), colonyforming unit-granulocyte/macrophage (CFU-GM), and CFU-GEMM synergistically with various cytokines including erythropoietin (Epo), G-CSF, and IL-6.l3-I5 However, Rennick et all5 reported the antagonizing effect of IL-4 on the IL-3-dependent murine CFU-GM and CFU-GEMM. In human system, these divergent effects of IL-4 have also been demonstrated; human IL-4 stimulates with G-CSFdependent colony formation,I6 whereas IL-4 inhibits the growth of IL-3-supported myeloid pr~genitors,'~.'' macrophage-CSF-or GM-CSF-dependent human macrophage progenitors (CFW-M),'* and IL-3-dependent BFU-E.I9
IL-6 was originally demonstrated to act on the proliferation and differentiation of B cells and to induce Ig production." Further studies have shown that IL-6 also interacts with cytokines, especially with IL-3 and IL-4; both of them can induce the proliferation of multipotent stem cells.14~21~24 These effects are dependent in part on shortening the Go phase of the cell cycle in individual stem cells.2' Hoang et aIz5 have reported the synergism between IL-3 and IL-6 in the proliferation of the leukemic blast colonies in some AMLcases. 
Concentration of IL-4 (Ulml)
In the present report, we attempted to clarify the potential correlation between the CD34 expression of AML blasts and their response to IL-4 and/or IL-6.
MATERIALS AND METHODS

AML blast cells.
Leukemic blast cells from 40 patients with AML were studied. Diagnosis of AML was based on the French-American-British (FAB) classification of acute leukemia. Patient characteristics are shown in Table 1 . Peripheral blood mononuclear cells (PBMC) were obtained by Ficoll-Hypaque densitygradient centrifugation, and T cells were removed by using CD2conjugated immunomagnetic beads (Dynabeads M-450; Dynal AS., Oslo, Norway). Adherent cells were depleted from the remaining cells by incubating the cell suspension (2 x 106/mL) for 1 hour in a Petri dish. These nonadherent and T-cell-depleted AML blasts were used for the following assays.
Leukemic blast cells were phenotyped with an indirect immunofluorescence technique.26 For immunofluorescence assays, mouse IgGl conjugated to fluorescein Immunofluorescence assays.
-_ _
(FITC) was used as a negative control. Unconjugated primary monoclonal antibodies used were as follows: anti-HLA-DR and anti-CD34 (HPCA-1) were obtained from Becton Dickinson Monoclonal Center (Mountain View, CA); anti-CD10 (J5), anti- CD34' leukemic cells were isolated from six CD34+ AML cases through positive selection by using immunomagnetic beads. Briefly, nonadherent PBMC were incubated with CD34 (HPCA-1) for 30 minutes at 37°C. They were washed with phosphate-buffered saline containing 2% fetal calf serum (FCS), and incubated with antimouse goat Ig-conjugated immunomagnetic beads (Dynal AS.) for 30 minutes at 37°C. Then, CD34' leukemic blasts were collected by using a MPC-1 magnet (Dynal A.S.). After overnight incubation at 37"C, immunomagnetic beads were detached from the CD34' blasts. These highly enriched CD34+ leukemic blasts were also used to evaluate blast colony formation.
Recombinant human (rh) IL-3, IL-4, and IL-6 were obtained from Genzyme (Boston, MA). rhG-CSF and rhEpo were gifts from Chugai Pharmaceutical Co (Tokyo, Japan); their specific activities were 108 U/mg protein and 10s Uimg protein, respectively. rhGM-CSF was kindly provided by Sumitomo Pharmaceutical (Tokyo, Japan) (specific activity, lo9 U/mg protein).
Proliferation of leukemic blasts in response to IL-4 and IL-6 was evaluated by measuring the 3H-thymidine ('H-TdR) incorporation. Briefly, 1 x lo5 blast cells were cultured in the presence of IL-4 (100 UlmL), IL-6 (100 UlmL), or no growth factor, ie, control. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Table 2. plastic 96-microwell plate at a concentration of 2 X lo4 cells/well and 1 x lo4 cellshwell in 0.1 mL medium, respectively. The mixtures were incubated under 100% humidity with 5% CO, in air at 37°C for 7 days in the presence of different growth factors. Compact colonies consisting of greater than 20 cells were enumerated as a leukemic blast colony under an inverted microscope. Cells picked up from individual colonies were placed directly on slides and stained with Giemsa solution to confirm the morphologic similarity of colony-derived cells to leukemic blasts from each patient.
In our previous experiments, IL-3, GM-CSF, and G-CSF showed the maximum stimulation for blast colony formation at 500 U/mL, 1,000 UlmL, and 100 ng/mL, re~pectively.)~ These concentrations were used throughout this study. We also reported that the synergistic action of Epo with IL-3 or GM-CSF was obtained at 1 U/mL of E~o .~
In addition, in one case in which Epo alone could support blast colony formation the maximum stimulation was observed at 10 U/mL of Epo (data not shown). Accordingly, 10 U/mL of Epo was used throughout this study.
RESULTS
Sugace antigen expression.
Results of the immunofluorescence analysis are shown in Table 1 . Leukemic blasts from 21 of 40 patients (patients 1 through 21) were positive (>15%) for CD34 and those from the remaining 19 patients (patients 22 through 40) were negative (<3%). Thirty-six of these patients showed positivity for HLA-DR, in the remaining 13 patients.
while none of them showed positivity for a series of B-cell antigens including CDlO and CD19 (< 3%). Figure 1 shows 3H-TdR incorporation of blast cells when they were incubated with IL-4 alone. IL-4 alone stimulated DNA synthesis in 10 of 19 CD34' AML examined (patients 1, 2, 4, 5, 6, 7, 12, 13, 19 , and 20) and 7 of 16 CD34-AML examined (patients 23, 24, 25, 26, 28 , 37, and 40) when the positive stimulation was defined as a stimulation index (S.I.) > 2.0 (S.I.: mean cpm with different growth factors/control cpm). In four cases (patients 29, 30, 34, and 35) more than 30% suppression of the spontaneous DNA synthesis was observed. However, IL-6 alone could not stimulate DNA synthesis in any of the cases (data not shown).
Doseresponse curves of IL-4 for leukemic blast colony formation in patients 2, 17, 19, and 23 are illustrated in Fig 2. The stimulatory effects of IL-4 on leukemic blast colony formation reached a plateau level at a concentration of 100 U/mL. IL-4 alone supported leukemic blast colony formation in 10 of 21 CD34' AML and in 5 of 19 CD34-AML ( Table 2) .
Either IL-3, GM-CSF, or G-CSF alone had potent effects on the blast colony formation in both CD34' and CD34-DNA synthesis.
Effects of IL-4 on leukemic blast colony formation.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org AML, while Epo alone showed no effect, except in patient 34. The synergistic or suppressive effects of IL-4 were also observed in both CD34+ and CD34-AML. Dose-response curves of leukemic blast colonies formed by the addition of IL-3 with or without IL-4 (100 U/mL) in two cases (patients 2 and 35) are shown in Fig 3. In patient 2, the additional IL-4 acted synergistically with IL-3, whereas in patient 35 the additional IL-4 exerted a suppressive effect on IL-3dependent colony growth. The stimulatory effects of IL-3 reached a plateau level at a concentration of 500 UlmL, and the doses of IL-3 for the half-maximum stimulation were almost identical irrespective of the presence of IL-4. Summarized data were shown in Table 2 . The additional IL-4 showed synergistic enhancement of IL-3-, GM-CSF-, and G-CSF-dependent colony formation in 6 of 19,4 of 21, and 6 of 20 cases examined, respectively. The combination of IL-4 plus Epo resulted in synergistic enhancement of IL-4-dependent (7 of 9 cases examined) blast colony formation. On the other hand, IL-4 suppressed IL-3-, GM-CSF-, G-CSF-, and Epo-dependent colony formation in 6 of 19, 9 of 21, 7 of 20, and 1 of 1 cases examined, respectively.
Leukemic blast colony formation supported by IL-6 alone was observed only in patient 17. In this case, colony numbers reached a plateau at a concentration of 100 U/mL of IL-6 (data not shown). The relationship between concentrations of IL-6 in the presence of IL-3 (500 U/mL) or IL-4 (100 UlmL) and numbers of blast colonies formed on day 7 is illustrated in Figs 4A and 4B , respectively. The colony formation was increased in a dose-dependent manner and reached a plateau in the presence of 100 U/mL of IL-6 in both situations.
In addition, serial observations of leukemic blast colony formation in patient 18 showed that numbers of colonies supported by IL-3 (500 U/mL), IL-4 (100 U/mL), IL-3 plus IL-6 (100 U/mL), or IL-4 plus IL-6 showed each peak level on day 7 or day 8 of the cultures (Fig 5) . Accordingly, the addition of 100 U/mL of IL-6 and the colony counting on day 7 of the cultures were used for evaluating the synergistic action of IL-6 with IL-3 or IL-4.
The results are shown in Table 3 . The additional IL-6 synergistically enhanced both IL-3-and IL-4-dependent blast colony formation. This synergism was observed in 10 of 12 IL-3-responding CD34' and in 7 of 9 IL-4-responding CD34' AML cases. However, such synergistic effect of IL-6 was observed in the minority of CD34-AML cases; 1 of 10 IL-3-responding cases and 3 of 7 IL-4-responding cases.
In further experiments, we studied the effects of IL-3 (patients 2 and 5 ) and IL-4 (patients 2 and 23) on leukemic blast colony formation in the presence or absence of IL-6 at a maximum dose (100 U/mL). Results are illustrated in Figs 6A and 6B, respectively. In both situations, the stimulatory effects on the colony growth reached a plateau level at a concentration of 100 U/mL for IL-3 or IL-4. Numbers of colonies formed with IL-6 were consistently greater than those with either IL-3 or IL-4 alone, at different concentrations examined. The slope of curves were similar; concentrations of IL-3 or IL-4 giving half of the maximum stimulation did not appear to be affected by the addition of IL-6.
To exclude the possibility that these phenomena might be mediated by contaminated accessory cells, we also examined effects of IL-4 and IL-6 on blast colony formation from purified CD34+ leukemic blast populations. The results are shown in Table 4 . The divergent effect of IL-4 in the presence of IL-3 or G-CSF and the synergistic effect of IL-6 with IL-3 or IL-4 were also observed in CD34' blast populations. The growth patterns of CD34' leukemic blasts in response to various growth factors were almost similar to those of unfractionated (nonadherent, T-cell-depleted) leukemic blasts in each case.
Effects of IL-6 on leukemic blast colony growth.
Effects of IL-4 and IL-6 on purified CD34' blasts.
DISCUSSION
In our study, all of the 40 patients studied were selected on the basis that AML blasts did not express B-cell antigens such as CDlO and CD19. Accordingly, their responses to these B-cell growth factors, IL-4 and IL-6, are probably not Table 2 .
dependent on the B-lymphoid-directed differentiation of leukemic blasts. IL-4 alone could stimulate either DNA synthesis or blast colony formation in 24 of 40 cases. IL-4 also showed synergistic effects on blast colony growth with IL-3, GM-CSF, G-CSF, and/or Epo. However, IL-4 alone also could suppress the spontaneous DNA synthesis, and the additional IL-4 suppressed IL-3-, GM-CSF-, G-CSF-, and/or Epwdependent blast colony formation. Vellenga et all7 also demonstrated the similar divergent effects of IL-4 on IL-3-and G-CSF-dependent blast colony growth. In the present study, the divergent effects of IL-4 on the proliferation of blasts are not restricted by coexisting growth factors, CD34 positivities, or types of AML according to the FAB classification. Thus, it is suggested that the dual regulatory function of IL-4 for proliferation of AML blasts is not involved in the myeloid differentiation pathway of leukemic progenitors. Furthermore, IL-4 probably exerts its divergent effects not through affecting the sensitivity of blast cells to other growth factors, because the dose of IL-3 to support the half-maximum number of blast colonies was almost similar irrespective of the additional IL-4. This finding is compatible with a recent report indicating that IL-4 inhibits IL-3-or GM-CSF-dependent growth of cell line FDC-PI through a direct effect on target cells. 27 In contrast, IL-6 is demonstrated to act mainly as a costimulatory factor for the IL-3-and IL-4-dependent proliferation of AML blasts, and this synergism was preferentially observed in CD34' AML. As for the synergistic action of IL-6, two possibilities for its mechanism are conceivable. The first possibility is that IL-6 may act as a permissive factor which induces leukemic progenitors to enter into the cell cycle from a Go phase as demonstrated in normal multipotential stem cells.21 On the other hand, chronological colony counting showed that the combination of IL-6 with either IL-3 or IL-4 did not shorten the time course for the emergence of leukemic blast colonies. The second possibility is that IL-6 may increase the sensitivity of clonogenic leukemic blast cells to IL-3 or IL-4. This possibility is also unlikely because the additional IL-6 did not affect the dose-response curves of leukemic blast colonies induced by IL-3 or IL-4. Accordingly, these data suggest the presence of clonogenic cell populations requiring IL-6 plus either IL-3 or IL-4 for their growth.
Recent reports indicate that adherent blast cell populations from AML, which lacked colony-forming capacity, produced CSFs such as G-CSF, GM-CSF, and probably IL-lp, and that these CSFs played an important role in the growth of leukemic progenitors in vitro." IL-4 is known to suppress the capacity of monocyte to secrete IL-lfLZ9 IL-6 has been reported to suppress IL-1p production from PBMC.M To exclude the complicated interaction of these cytokines in the proliferation of leukemic progenitors, we studied both nonadherent, T-cell-depleted AML blasts and purified CD34+ AML blasts. Results obtained were similar in both populations in each AML case. Accordingly, the effects of IL-4 and IL-6 demonstrated in this study could be ascribed to their direct action on leukemic progenitor cells, neither to the modulation by accessory cells or adherent AML blast cells, nor to the interaction of these cells. However, there remains the possibility that IL-4 and IL-6 exert their effects through modulating some autocrine growth factors produced by blasts themselves.
Thus, IL-4 and IL-6 play an important role in the proliferation of AML blasts either in the absence or presence of other growth factors. IL-4 has divergent effects on the growth of leukemic progenitors in both CD34' and CD34-AML. IL-6 stimulates the proliferation of leukemic blasts synergistically with a multipotent growth factor such as IL-3 and IL-4 preferentially in CD34' AML cases. These phenomena should be clarified by further studies, including an analysis of IL-4 or IL-6 receptors3' on leukemic blasts and/or the possible modulatory action of IL-4 or IL-6 on the production of autocrine growth factors.
